英特格拉生命科学控股公司发布最新业绩指引,预计2026财年第一季度报告营收将介于3.75亿美元至3.90亿美元之间。这一预期范围反映出公司对核心业务增长的稳健展望,同时也为市场提供了衡量其短期财务表现的关键指标。
英特格拉生命科学控股公司发布最新业绩指引,预计2026财年第一季度报告营收将介于3.75亿美元至3.90亿美元之间。这一预期范围反映出公司对核心业务增长的稳健展望,同时也为市场提供了衡量其短期财务表现的关键指标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.